



Universiteit
Leiden
The Netherlands

ASO visual abstract: nationwide use and outcome of surgery for locally advanced pancreatic cancer following induction chemotherapy

Stoop, T.F.; Seelen, L.W.F.; Van't Land, F.R.; Lutchman, K.R.D.; Dieren, S. van; Lips, D.J.; ... ; Dutch Pancreatic Canc Grp

Citation

Stoop, T. F., Seelen, L. W. F., Van't Land, F. R., Lutchman, K. R. D., Dieren, S. van, Lips, D. J., ... Draaisma, W. (2024). ASO visual abstract: nationwide use and outcome of surgery for locally advanced pancreatic cancer following induction chemotherapy. *Annals Of Surgical Oncology*. doi:10.1245/s10434-023-14790-9

Version: Publisher's Version

License: [Licensed under Article 25fa Copyright Act/Law \(Amendment Taverne\)](#)

Downloaded from: <https://hdl.handle.net/1887/3720961>

Note: To cite this publication please use the final published version (if applicable).



ASO VISUAL ABSTRACT

ASO Visual Abstract: Nationwide Use and Outcome of Surgery for Locally Advanced Pancreatic Cancer Following Induction Chemotherapy

Thomas F. Stoop, MD^{1,2,3}, Leonard W. F. Seelen, MD⁴, Freek R. van't Land, MD⁵, Kishan R. D. Lutchman, BSc^{1,2}, Susan van Dieren, MSc, PhD^{1,2}, Daan J. Lips, MD, PhD⁶, Erwin van der Harst, MD, PhD⁷, Geert Kazemier, MD, PhD^{2,8}, Gijs A. Patijn, MD, PhD⁹, Ignace H. de Hingh, MD, PhD¹⁰, Jan H. Wijsman, MD, PhD¹¹, Joris I. Erdmann, MD, PhD^{1,2}, Sebastiaan Festen, MD, PhD¹², Bas Groot Koerkamp, MD, PhD⁵, J. Sven D. Mieog, MD, PhD¹³, Marcel den Dulk, MD, PhD^{14,15}, Martijn W. J. Stommel, MD, PhD¹⁶, Olivier R. Busch, MD, PhD^{1,2}, Roeland F. de Wilde, MD, PhD⁵, Vincent E. de Meijer, MD, PhD¹⁷, Wouter te Riele, MD, PhD⁴, I. Quintus Molenaar, MD, PhD⁴, Casper H. J. van Eijck, MD, PhD⁵, Hjalmar C. van Santvoort, MD, PhD⁴, and Marc G. Besselink, MD, MSc, PhD^{1,2}  on behalf of for the Dutch Pancreatic Cancer Group

¹Amsterdam UMC, location University of Amsterdam, Department of Surgery, Amsterdam, The Netherlands;

²Cancer Center Amsterdam, Amsterdam, The Netherlands; ³Division of Surgical Oncology, Department of Surgery, University of Colorado Anschutz Medical Campus, Aurora, CO; ⁴Department of Surgery, Regional Academic Cancer Center Utrecht, University Medical Center Utrecht/St. Antonius Hospital Nieuwegein, Nieuwegein, The Netherlands;

⁵Department of Surgery, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands;

⁶Department of Surgery, Medisch Spectrum Twente, Enschede, The Netherlands; ⁷Department of Surgery, Maasstad Hospital, Rotterdam, The Netherlands; ⁸Amsterdam UMC, location Vrije University, Department of Surgery, Amsterdam, The Netherlands; ⁹Department of Surgery, Isala Clinics, Zwolle, The Netherlands; ¹⁰Department of Surgery, Catharina Hospital, Eindhoven, The Netherlands; ¹¹Department of Surgery, Amphia Hospital, Breda, The Netherlands; ¹²Department of Surgery, OLVG, Amsterdam, The Netherlands; ¹³Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands; ¹⁴Department of Surgery, Maastricht University Medical Center, Maastricht, The Netherlands;

¹⁵Department of General, Visceral and Transplant Surgery, University Hospital, Aachen, Germany; ¹⁶Department of Surgery, Radboud University Medical Center, Nijmegen, The Netherlands; ¹⁷Department of Surgery, University Medical Center Groningen, Groningen, The Netherlands

Multicenter retrospective study including all patients who underwent resection for locally advanced pancreatic cancer (LAPC) following chemo(radio)therapy in all 16

Dutch pancreatic surgery centers (2014–2020), registered in the mandatory Dutch Pancreatic Cancer Audit (<https://doi.org/10.1245/s10434-023-14650-6>). LAPC was defined as arterial involvement > 90° and/or portomesenteric venous > 270° involvement or occlusion. Resection of LAPC following chemo(radio)therapy is infrequently performed in the Netherlands, albeit with acceptable morbidity, mortality, and OS. Given these findings, a structured nationwide approach involving international centers of excellence would be needed to improve selection of patients with LAPC for surgical resection following induction therapy.


Thomas F. Stoop and Leonard W. F. Seelen contributed equally to this work

© Society of Surgical Oncology 2024

T. F. Stoop, MD
e-mail: t.f.stoop@amsterdamUMC.nl

M. G. Besselink, MD, MSc, PhD
e-mail: m.g.besselink@amsterdamUMC.nl

Nationwide Use and Outcome of Surgery for Locally Advanced Pancreatic Cancer Following Induction Chemotherapy



DUTCH PANCREATIC CANCER GROUP Anniek Vlijm, MD, PhD; Bert A. Bonsing, MD, PhD; C. Yung Nio, MD, PhD; Derik-Jan de Groot, MD, PhD; Elske Gootjes, MD, PhD; Eran van Veldhuisen, MD, PhD; Eric Manusama, MD, PhD; Fenny Wit, MD, PhD; Freek Daams, MD, PhD; Geert Cirkel, MD, PhD; Geertjan van Tienhoven, MD, PhD; Irene van Hellemond, MD, PhD; Johanna W. Wilmink, MD, PhD; Judith de Vos-Geelen, MD, PhD; Koop Bosscha, MD, PhD; Leonie J. Mekenkap, MD, PhD; Maarten W. Nijkamp, MD, PhD; Maartje Los, MD, PhD; Marion B. van der Kolk, MD, PhD; Marjolein Homs, MD, PhD; Mark Ramaekers, MD; Mike S. Liem, MD, PhD; Miriam Wumkes, MD, PhD; Nynke Michiels, MD; Ronald van Dam, MD, PhD; Rutger T. Theijse, BSc; Saskia Luelmo, MD, PhD; Thomas L. Bollen, MD, PhD; Ulf Neumann, MD, PhD; Vincent Nieuwenhuijs, MD, PhD; Werner Draaisma, MD, PhD

DISCLOSURE Thomas F. Stoop, Casper H.J. van Eijck, Hjalmar C. van Santvoort, and Marc G. Besseling received two grants from Dutch Cancer Society (KWF) and Deltaplan Alvleesklierkanker for the Dutch PREOPANC-4 project on the multidisciplinary management of LAPC. Furthermore, Thomas F. Stoop is granted by Prins Bernhard Cultuurfonds (Jan de Ruijsscher/Pia Huisman Fonds).

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.